Chris Gunter

Chris Gunter

Auto-generated profile, based on publicly available information

Chris Gunter

Social and Behavioral Research Branch, National Human Genome Research Institute, Bethesda, MD 20892, USA; Office of the Director, National Human Genome Research Institute, Bethesda, MD 20892, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2014 in Nature
Verified
Journal Article
Open access
PDF file
DMD. G. MacArthur
D. G. MacArthur
TMT. A. Manolio
T. A. Manolio
DDD. P. Dimmock
D. P. Dimmock
HHeidi Rehm
Heidi Rehm
JSJ. Shendure
J. Shendure
CGC. Gunter
C. Gunter
Acceleration in discovery of rare genetic variants possibly linked with disease may mean an increased risk of false-positive reports of causality; this Perspective proposes guidelines to distinguish disease-causing sequence variants from the many potentially functional variants in a human genome, and to assess confidence in their pathogenicity, and highlights priority areas for development. The wide-scale availability of high-throughput DNA sequencing technologies means that data on genetic variation in human diseases are accumulating rapidly. In this Perspective, Daniel MacArthur and colleagues sound a note of caution, pointing out that up to a quarter of reported disease-linked mutations have been found to either be common polymorphisms or have lacked sufficient evidence for pathogenicity. The authors discuss the key challenges associated with assessing sequence variants in human disease and propose guidelines for the robust differentiation between disease-causing genetic variants and other variants present in the human genome. They highlight several areas where research and resource development are urgently needed if genomic research findings are to be successfully translated into the clinical diagnostic setting. The discovery of rare genetic variants is accelerating, and clear guidelines for distinguishing disease-causing sequence variants from the many potentially functional variants present in any human genome are urgently needed. Without rigorous standards we risk an acceleration of false-positive reports of causality, which would impede the translation of genomic research findings into the clinical diagnostic setting and hinder biological understanding of disease. Here we discuss the key challenges of assessing sequence variants in human disease, integrating both gene-level and variant-level support for causality. We propose guidelines for summarizing confidence in variant pathogenicity and highlight several areas that require further resource development.

6 June 2007 in Nature
Verified
Journal Article
Open access
PDF file
NSNCI-NHGRI Working Group on Replication in Association Studies
NCI-NHGRI Working Group on Replication in Association Studies
SCStephen J. Chanock
Stephen J. Chanock
TMTeri Manolio
Teri Manolio
MBMichael Boehnke
Michael Boehnke
EBEric Boerwinkle
Eric Boerwinkle
FCFrancis S. Collins
Francis S. Collins
What constitutes replication of a genotype–phenotype association, and how best can it be achieved? Reviews of the many genetic association studies published recently give pause for thought: there are many false positives and questionable genotype–phenotype associations in the literature. A working group set up by the National Cancer Institute and National Human Genome Research Institute has been tackling the thorny question of what constitutes replication of a genotype–phenotype association, and the initial results are published this week. Guidelines on best practice for reporting initial and replication studies are presented. But it's clear that a series of studies is sometimes necessary to confirm critical genotype–phenotype associations.

15 December 2015 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
SOSam S. Oh
Sam S. Oh
JGJoshua Galanter
Joshua Galanter
NTNeeta Thakur
Neeta Thakur
Maria Pino-YanesMaria Pino-Yanes
Maria Pino-Yanes
NBNicolas E. Barcelo
Nicolas E. Barcelo
EBEsteban G. Burchard
Esteban G. Burchard
Esteban Gonzalez Burchard and colleagues explore how making medical research more diverse would aid not only social justice but scientific quality and clinical effectiveness, too.

28 October 2020 in Nature
Verified
Journal Article
Closed access
PDF file
EGEric D. Green
Eric D. Green
CGChris Gunter
Chris Gunter
LBLeslie G. Biesecker
Leslie G. Biesecker
VFValentina Di Francesco
Valentina Di Francesco
CECarla L. Easter
Carla L. Easter
TMTeri A. Manolio
Teri A. Manolio

1 June 1998 in Journal of Biological Chemistry
Verified
Journal Article
Open access
VBVictoria Brown
Victoria Brown
KSKersten Small
Kersten Small
LLLisa Lakkis
Lisa Lakkis
Yue FengYue Feng
Yue Feng
CGChris Gunter
Chris Gunter
SWStephen T. Warren
Stephen T. Warren
Fragile X syndrome is caused by the transcriptional silencing of the FMR1 gene due to a trinucleotide repeat expansion. The encoded protein, Fmrp, has been found to be a nucleocytoplasmic RNA-binding protein containing both KH domains and RGG boxes that associates with polyribosomes as a ribonucleoprotein particle. RNA binding has previously been demonstrated with in vitro-translated Fmrp; however, it remained uncertain whether the selective RNA binding observed was an intrinsic property of Fmrp or required an associated protein(s). Here, baculovirus-expressed and affinity-purified FLAG-tagged murine Fmrp was shown to bind directly to both ribonucleotide homopolymers and human brain mRNA. FLAG-Fmrp exhibited selectivity for binding poly(G) > poly(U) > poly(C) or poly(A). Moreover, purified FLAG-Fmrp bound to only a subset of brain mRNA, including the 3' untranslated regions of myelin basic protein message and its own message. Recombinant isoform 4, lacking the RGG boxes but maintaining both KH domains, was also purified and was found to only weakly interact with RNA. FLAG-purified I304N Fmrp, harboring the mutation of severe fragile X syndrome, demonstrated RNA binding, in contrast to previous suggestions. These data demonstrate the intrinsic property of Fmrp to selectively bind RNA and show FLAG-Fmrp as a suitable reagent for structural characterization and identification of cognate RNA ligands.

1 November 1998 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
CGChris Gunter
Chris Gunter
WPWilliam Paradee
William Paradee
Dana C. CrawfordDana C. Crawford
Dana C. Crawford
KMKellen A. Meadows
Kellen A. Meadows
JNJames Newman
James Newman
SWStephen T. Warren
Stephen T. Warren
In at least 98% of fragile X syndrome cases, the disease results from expansion of the CGG repeat in the 5′ end of FMR1. The use of microsatellite markers in the FMR1 region has revealed a disparity of risk between haplotypes for CGG repeat expansion. Although instability appears to depend on both the haplotype and the AGG interspersion pattern of the repeat, these factors alone do not completely describe the molecular basis for the linkage disequilibrium between normal and fragile X chromosomes, in part due to instability of the marker loci themselves. In an effort to better understand the mechanism of dynamic mutagenesis, we have searched for and discovered a single nucleotide polymorphism in intron 1 of FMR1 and characterized this marker, called ATL1, in 564 normal and 152 fragile X chromosomes. The G allele of this marker is found in 40% of normal chromosomes, in contrast to 83% of fragile X chromosomes. Not only is the G allele exclusively linked to haplotypes over-represented in fragile X syndrome, but G allele chromosomes also appear to transition to instability at a higher rate on haplotypes negatively associated with risk of expansion. The two alleles of ATL1 also reveal a highly significant linkage disequilibrium between unstable chromosomes and the 5′ end of the CGG repeat itself, specifically the position of the first AGG interruption. The data expand the number of haplotypes associated with FMR1 and specifically allow discrimination, by ATL1 alleles, of single haplotypes with differing predispositions to expansion. Such haplotypes should prove useful in further defining the mechanism of dynamic mutagenesis.